Partnership to target diagnostic technology
< Press Release 5 May 2009 New
investment partnership to target medical diagnostic
technology A new investment partnership is looking to
invest up to $10 million developing globally-focused medical
diagnostics businesses in New Zealand. The partnership is
between the New Zealand Venture Investment Fund and the
private investment company, New Zealand Diagnostics Ltd
(NZDx). It aims to invest between $8 million and $10
million into new medical diagnostics ventures. NZDx
director William Randall said that the international
diagnostics market is experiencing rapid growth and is worth
around US$30 billion. “There are some very promising
technologies emerging in New Zealand which could have
considerable commercial potential. As the cost of
healthcare rises around the world, the sector is looking at
ways to deliver better and more efficient treatment, and new
diagnostic technologies allow that. “We are active
investors in the sector. We have invested in two exciting
new ventures – eBonz, which has developed 3D anatomically
based models of all joints in the human body, and Manawatu
Diagnostics, which is developing human fertility medical
diagnostic technology.” NZVIF chief executive Franceska
Banga said the partnership was an exciting prospect given
New Zealand’s strong background in life sciences
technology. “New Zealand has a history of excellence in
life sciences research. NZDxhas considerable experience in
developing new businesses and, in particular, considerable
knowledge of the medical diagnostics sector.
“We believe
there are significant investment opportunities in medical
diagnostics technology in New Zealand. With this
partnership, we hope to see greater investment in new
innovations which have the potential to advance to the
commercial stage in global markets.” NZDx's partnership
with NZVIF is through NZVIF’s Seed Co-Investment Fund.
Through the fund, NZVIF is investing $40 million into early
stage companies with strong potential for high growth,
alongside investments made by its partners. This is the
ninth partnership NZVIF has entered into through the Seed
Co-Investment Fund, although this agreement with NZDx is
replacing an earlier partnership with Chrysalis, a life
sciences investment company. Through these partnerships,
NZVIF has to date invested over $17.6 million into 21
companies. ends